 Intravenous carboplatin recurrent malignant glioma phase II study Thirty patients recurrent malignant glioma intravenous IV carboplatin CBDCA weeks dose patients recurrent tumor prior radiotherapy prior chemotherapy assessable patients treatment weeks stable disease progressive disease total response responses rate median time progression MTP weeks patients MTP patients weeks toxic effects hematologic thrombocytopenia granulocytopenia doses neurotoxicity renal toxicity results CBCDA weeks active patients recurrent malignant gliomas hematologic toxicity mild dose response rate